Arrowhead Pharmaceuticals Establishes Verona, Wisconsin, Campus
05/10/2022
The new campus, which will consist of two buildings, will complement the company’s existing 111,000-square-foot research and development facility in Madison.
The first building is an approximately 125,000-square-foot laboratory and office facility that will support process development and analytical activities. The second is an approximately 160,000-square-foot GMP drug manufacturing facility, which company leaders say will be critical to Arrowhead’s global operations.
“We have seen firsthand the tremendous value that the Wisconsin biotech ecosystem can afford a nimble and aggressive company like Arrowhead,” said Christopher Anzalone, Ph.D., president and CEO of Arrowhead Pharmaceuticals. “The local community has supported us graciously over the last decade, so we look forward to this expansion contributing to the further growth in the region as we work to make medicines with a potential global impact.”
Wisconsin Economic Development Corporation (WEDC) is assisting Arrowhead Pharmaceuticals with $2.5 million in performance-based business development tax credits, which the company will receive if it meets or exceeds job creation and capital investment goals by the end of 2026. The city of Verona is also assisting the project with up to $16 million in tax incremental financing for site improvements.
“WEDC is pleased to partner with Arrowhead because they have the potential to transform health care, and all of our lives, through innovation, persistence, and collaboration,” said Missy Hughes, secretary and CEO of WEDC. “Arrowhead joins a growing list of biopharmaceutical companies that have chosen to locate in Wisconsin because of the strategic investments our state has made in worker education and training, infrastructure, and strong communities in recent years.”
Based in Pasadena, California, Arrowhead Pharmaceuticals is developing new medicines for intractable diseases by silencing the genes that cause them. It does this by tapping into a process called RNA interference, or RNAi. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein.
Project Announcements
AmplifyBio Establishes New Albany, Ohio, Facility
05/25/2022
Buffalo River Truss Relocates-Expands Lobelville, Tennessee, Operations
05/25/2022
Britain-Based Exurban Plans Fort Wayne, Indiana, Smelter Refinery
05/24/2022
South Korea-Based TYM-USA and Branson Plan Rome, Georgia, Tractor Factory
05/24/2022
Hyundai Motor Group Plans Bryan County, Georgia, Electric Vehicle-Battery Plant
05/23/2022
UTAC Establishes Redford, Michigan, Operations
05/23/2022
Most Read
-
The Evolution of the Megasite
Q2 2022
-
36th Annual Corporate Survey: Executives Focus on Labor, Energy, Shipping Costs
Q1 2022
-
Rail Gains Advantage Amidst Supply Chain Snarls
Q2 2022
-
The 2021 Top States for Doing Business Reflect Their Locational Advantages
Q3 2021
-
2021 Gold & Silver Shovel Awards Recognize State and Local Economic Development Efforts
Q2 2021
-
Innovative and Collaborative Design Sets the Stage for Life Science Innovation
Q2 2022
-
Trends in Data Center Site Selection
Q2 2022